Literature DB >> 20132625

Can hepatitis B virus infection predict tuberculosis treatment liver toxicity? Development of a preliminary prediction rule.

L de Castro1, P E A A do Brasil, T P Monteiro, V C Rolla.   

Abstract

BACKGROUND: Liver toxicity due to tuberculosis (TB) treatment is a frequent cause of treatment interruption, and may sometimes lead to a change in therapy to a less potent regimen.
OBJECTIVE: To estimate the risk of hepatotoxicity in patients with or without hepatitis B virus (HBV) infection receiving TB treatment and to develop a clinical prediction rule.
DESIGN: A prospective observational follow-up was conducted. Data from 154 patients who underwent TB treatment were analysed. Crude risk ratios were estimated and a Cox proportional hazards model was fit.
RESULTS: The mean follow-up time was 187 days. Crude risk ratios showed that ethnicity, human immunodeficiency virus infection, multiple sexual partners, highly active antiretroviral treatment, and clinical forms of TB were possible predictors of liver toxicity. HBV infection and other sexually transmitted diseases showed considerable relative risk, although not statistically significant. The Cox proportional hazards model identified the following predictors of hepatotoxicity: White ethnicity, multiple sexual partners, high baseline alanine transferase and clinical forms of TB. Active HBV, indicated by the detection of surface antigen HBV, could predict hepatotoxicity, although with low precision.
CONCLUSION: Using this information, we were able to apply a score and draw a nomogram to estimate survival probabilities and median times to event for each patient.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20132625

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  4 in total

1.  Viral hepatitis prevalence in patients with active and latent tuberculosis.

Authors:  Hesam Ahmadi Nooredinvand; David W Connell; Mahmoud Asgheddi; Mohammed Abdullah; Marie O'Donoghue; Louise Campbell; Melissa I Wickremasinghe; Ajit Lalvani; Onn Min Kon; Shahid A Khan
Journal:  World J Gastroenterol       Date:  2015-08-07       Impact factor: 5.742

Review 2.  Drug Induced Liver Injury: Review with a Focus on Genetic Factors, Tissue Diagnosis, and Treatment Options.

Authors:  Tawfik Khoury; Ayman Abu Rmeileh; Liron Yosha; Ariel A Benson; Saleh Daher; Meir Mizrahi
Journal:  J Clin Transl Hepatol       Date:  2015-06-15

3.  Hepatitis B Co-Infection is Associated with Poorer Survival of HIV-Infected Patients on Highly Active Antiretroviral Therapy in West Africa.

Authors:  Nimzing G Ladep; Oche O Agbaji; Patricia A Agaba; Auwal Muazu; Placid Ugoagwu; Godwin Imade; Graham S Cooke; Livia Vivas; Sheena Mc Cormack; Simon D Taylor-Robinson; John Idoko; Phyllis Kanki
Journal:  J AIDS Clin Res       Date:  2013-06-29

4.  Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury.

Authors:  Wan Soo Kim; Sang Soo Lee; Chang Min Lee; Hong Jun Kim; Chang Yoon Ha; Hyun Jin Kim; Tae Hyo Kim; Woon Tae Jung; Ok Jae Lee; Jeong Woo Hong; Hyun Seon You; Hyun Chin Cho
Journal:  BMC Infect Dis       Date:  2016-02-01       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.